Search
Jun 4
Allucent at ASCO 2024
From McCormick Place during #ASCO24, we talk with Brian Abbott, MD, Allucent's Global Head of Oncology, about the latest trends in...
Jun 3
Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data at #ASCO24 and Moderna's broader oncology pipeline
At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen...
Jun 1
The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease
Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.
.png){kind=logo}
